GHRH-receptor agonism
The peptide activates pituitary GHRH receptors involved in growth-hormone signalling.
NXP / 10
Research profile
CJC-1295 DAC
5MGLong-acting GHRH-analogue research peptide
CJC-1295 DAC is a growth-hormone-releasing-hormone analogue modified with a drug-affinity complex designed to bind circulating albumin. It is distinct from CJC-1295 no-DAC and modified GRF presentations.
NEXPEP PRICE$79.00 AUDThe same current price shown throughout the Nexpep store.
Scientific context
What it does.
Controlled research uses CJC-1295 DAC to examine extended GHRH-receptor stimulation, growth-hormone pulse dynamics and downstream IGF-1 responses. The DAC modification materially changes exposure duration and study design.
Mechanism map
How the research
model works.
Albumin association
The DAC moiety forms a longer-lived association with albumin, extending exposure relative to no-DAC material.
Endocrine readout
Research measures growth-hormone and IGF-1 dynamics across a longer sampling window.
Study design
Research pairing
options.
These are experimental design concepts—not recommendations for human use, co-administration or dosing.
CJC-1295 no-DAC comparator
Directly tests the experimental effect of extended exposure.
Do not treat DAC and no-DAC products as interchangeable.Vehicle control
Establishes baseline endocrine and assay variability.
Match the extended sampling schedule used for the DAC arm.Unstacked control
CJC-1295 DAC alone provides the clearest formulation-level signal.
Avoid secretagogue combinations in the primary comparison.Interpretation controls
Important
limitations.
- CJC-1295 DAC is not represented as approved for human use.
- DAC and no-DAC formulations have materially different pharmacokinetics.
- Endocrine-active research requires predefined sampling, stopping and interpretation criteria.
Evidence trail